Equities

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Actions
  • Price (EUR)26.86
  • Today's Change0.000 / 0.00%
  • Shares traded750.00
  • 1 Year change-36.95%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
OPERATIONS
Net income(529)(652)(746)
Depreciation/depletion1.781.551.38
Non-Cash items132153275
Cash taxes paid, supplemental04.92--
Cash interest paid, supplemental3.295.0010
Changes in working capital(200)(16)(94)
Total cash from operations(595)(514)(563)
INVESTING
Capital expenditures(0.77)(1.52)(1.1)
Other investing and cash flow items, total0.1061249
Total cash from investing(0.67)60248
FINANCING
Financing cash flow items(11)(5.68)(5.79)
Total cash dividends paid------
Issuance (retirement) of stock, net461406398
Issuance (retirement) of debt, net(56)(35)0
Total cash from financing394366392
NET CHANGE IN CASH
Foreign exchange effects0.14(0.49)(2.02)
Net change in cash(201)(89)75
Net cash-begin balance/reserved for future use553642567
Net cash-end balance/reserved for future use352553642
SUPPLEMENTAL INCOME
Depreciation, supplemental1.781.551.38
Cash interest paid, supplemental3.295.0010
Cash taxes paid, supplemental04.92--
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.